A. Mathew, S. S. Devesa, J. F. Fraumeni, and W. Chow, Global increases in kidney cancer incidence, 1973???1992, European Journal of Cancer Prevention, vol.11, issue.2, pp.171-178
DOI : 10.1097/00008469-200204000-00010

S. Weikert, Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition, American Journal of Epidemiology, vol.167, issue.4, pp.438-446
DOI : 10.1093/aje/kwm321

A. Antonelli, A. Cozzoli, D. Zani, T. Zanotelli, M. Nicolai et al., The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol, BJU International, vol.17, issue.2, pp.296-300, 2007.
DOI : 10.1111/j.1464-410X.2005.05771.x

S. Eggener, O. Yossepowitch, J. Pettus, M. Snyder, R. Motzer et al., Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence, Journal of Clinical Oncology, vol.24, issue.19, pp.3101-3107, 2006.
DOI : 10.1200/JCO.2005.04.8280

T. Choueiri, B. Escudier, T. Powles, P. Mainwaring, B. Rini et al., Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1814-1837, 2015.
DOI : 10.1056/NEJMoa1510016

J. D. Hunt, O. L. Van-der-hel, G. P. Mcmillan, P. Boffetta, and P. Brennan, Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies, International Journal of Cancer, vol.128, issue.1, pp.101-108
DOI : 10.1002/ijc.20618

K. F. Adams, Body Size and Renal Cell Cancer Incidence in a Large US Cohort Study, American Journal of Epidemiology, vol.168, pp.268-277
DOI : 10.1093/aje/kwn122

W. H. Chow, G. Gridley, J. F. Fraumeni, and B. Järvholm, Obesity, Hypertension, and the Risk of Kidney Cancer in Men, New England Journal of Medicine, vol.343, issue.18, pp.1305-1311
DOI : 10.1056/NEJM200011023431804

J. Clague, Family history and risk of renal cell carcinoma: results from a casecontrol study and systematic meta-analysis. Cancer Epidemiol

K. R. Ong, Genotype-phenotype correlations in von Hippel-Lindau disease, Human Mutation, vol.8, issue.2, pp.143-149
DOI : 10.1002/humu.20385

H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs???Part A: Renal, Penile, and Testicular Tumours, European Urology, vol.70, issue.1
DOI : 10.1016/j.eururo.2016.02.029

W. Thoenes, S. Störkel, and H. Rumpelt, Human chromophobe cell renal carcinoma, Virchows Archiv B Cell Pathology Including Molecular Pathology, vol.308, issue.1, pp.207-224, 1985.
DOI : 10.1007/BF02890129

M. B. Amin, Papillary (Chromophil) Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 62 Cases, The American Journal of Surgical Pathology, vol.21, issue.6, pp.621-635
DOI : 10.1097/00000478-199706000-00001

C. F. Davis, The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma, Cancer Cell, vol.26, issue.3, pp.319-330
DOI : 10.1016/j.ccr.2014.07.014

D. Daga, R. Dana, and N. Kothari, Chromophobe renal cell carcinoma with sarcomatoid changes: case report and review of literature, Cent. Eur. J. Urol, vol.67, pp.31-34

D. Chao, COLLECTING DUCT RENAL CELL CARCINOMA:, The Journal of Urology
DOI : 10.1097/00005392-200201000-00018

J. R. Srigley and J. N. Eble, Collecting duct carcinoma of kidney, Semin. Diagn. Pathol, vol.15, pp.54-67

R. J. Motzer, J. Bacik, B. A. Murphy, P. Russo, and M. Mazumdar, Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.20, issue.1, pp.289-296, 2002.
DOI : 10.1200/JCO.2002.20.1.289

N. Kroeger, Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria, Cancer, vol.20, issue.16, pp.2999-3006
DOI : 10.1002/cncr.28151

L. Zini, U. Capitanio, P. Perrotte, C. Jeldres, S. Shariat et al., Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma, Urology, vol.73, issue.2, pp.342-348, 2009.
DOI : 10.1016/j.urology.2008.09.022

URL : https://hal.archives-ouvertes.fr/inserm-00353570

J. Kavolius, D. Mastorakos, C. Pavlovich, P. Russo, M. Burt et al., Resection of metastatic renal cell carcinoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2261-2267, 1998.
DOI : 10.1200/JCO.1998.16.6.2261

P. Russo, M. Synder, A. Vickers, V. Kondagunta, and R. Motzer, Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer
DOI : 10.1100/tswurol.2007.60

URL : https://doaj.org/article/f4a17d4bca2b49938b89e98b509fbc40

V. Khoo and L. Pyle, Radiotherapy and supportive care Clinical Progress in Renal Cancer, Oxford: Informa UK Ltd, pp.191-201, 2007.

D. Meerleer, G. Khoo, V. Escudier, and B. , Radiotherapy for renal-cell carcinoma, The Lancet Oncology, vol.15, issue.4, pp.170-177, 2014.
DOI : 10.1016/S1470-2045(13)70569-2

G. Weiss, K. Margolin, F. Aronson, M. Sznol, M. Atkins et al., A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma., Journal of Clinical Oncology, vol.10, issue.2, pp.275-81, 1992.
DOI : 10.1200/JCO.1992.10.2.275

S. Negrier, B. Escudier, C. Lasset, J. Douillard, J. Savary et al., Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.338, issue.18, pp.1272-1280, 1998.
DOI : 10.1056/NEJM199804303381805

K. Gupta, J. D. Miller, J. Z. Li, M. W. Russell, and C. Charbonneau, Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review, Cancer Treatment Reviews, vol.34, issue.3, pp.193-205
DOI : 10.1016/j.ctrv.2007.12.001

S. Buti, Chemotherapy in metastatic renal cell carcinoma today? A systematic review, Anti-Cancer Drugs, vol.24, pp.535-554
DOI : 10.1097/CAD.0b013e3283609ec1

J. Rak and R. Kerbel, Ras regulation of vascular endothelial growth factor and angiogenesis, Methods Enzymol, vol.333, pp.267-83, 2001.
DOI : 10.1016/S0076-6879(01)33062-8

R. Hilger, M. Scheulen, and D. Strumberg, The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer, Oncology Research and Treatment, vol.25, issue.6, pp.511-519, 2002.
DOI : 10.1159/000068621

H. Wang, U. Rapp, and J. Reed, Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria, Cell, vol.87, issue.4, pp.629-667, 1996.
DOI : 10.1016/S0092-8674(00)81383-5

J. Everitt, C. Walker, T. Goldsworthy, and D. Wolf, Altered expression of transforming growth factor-alpha: an early event in renal cell carcinoma development

L. Presta, H. Chen, O. Connor, and S. , Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, vol.57, pp.4593-4602, 1997.

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2
DOI : 10.1016/j.ejca.2008.10.026

A. Mejean and T. Lebret, Prise en charge du cancer r??nal m??tastatique, Progr??s en Urologie, vol.18, issue.7, pp.298-308, 2008.
DOI : 10.1016/S1166-7087(08)74558-5

J. Patard, H. Baumert, J. Correas, B. Escudier, H. Lang et al., Recommandations en Onco-Urologie 2010 : Cancer du rein, Progr??s en Urologie, vol.20, issue.4, pp.319-358, 2010.
DOI : 10.1016/S1166-7087(10)70048-8

R. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam et al., Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.17, issue.8, pp.2530-2570, 1999.
DOI : 10.1200/JCO.1999.17.8.2530

S. Negrier, B. Escudier, F. Gomez, J. Douillard, A. Ravaud et al., Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie, Annals of Oncology, vol.13, issue.9, pp.1460-1468, 2002.
DOI : 10.1093/annonc/mdf257

Y. Neuzillet and C. Coulange, Analyse critique des classifications pronostiques du cancer du rein m??tastatique, Progr??s en Urologie, vol.19, issue.6, pp.383-391, 2009.
DOI : 10.1016/j.purol.2008.10.011

B. Escudier, M. Goupil, C. Massard, and K. Fizazi, Sequential therapy in renal cell carcinoma, Cancer, vol.26, issue.suppl, pp.2321-2327, 2009.
DOI : 10.1002/cncr.24241

G. Latteux, S. Lebdai, N. Hoarau, S. Abadie-lacourtoisie, R. Delva et al., ??valuation de la prise en charge du cancer du rein m??tastatique ?? l?????re des th??rapies cibl??es. ??tude clinique r??trospective sur six ans, Prog En Urol [Internet]. mars 2013, pp.184-94, 2016.
DOI : 10.1016/j.purol.2012.09.014

M. Al-marrawi, B. Rini, L. Harshman, G. Bjarnason, L. Wood et al., The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients, Targeted Oncology, vol.116, issue.18, pp.203-209, 2013.
DOI : 10.1007/s11523-012-0252-7

A. Sacré, P. Barthélémy, C. Korenbaum, M. Burgy, P. Wolter et al., Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor, Acta Oncologica, vol.15, issue.3, pp.329-340, 2016.
DOI : 10.1111/j.1464-410X.2011.10186.x

R. Motzer, C. Barrios, T. Kim, S. Falcon, T. Cosgriff et al., Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.25, pp.2765-72, 2014.
DOI : 10.1200/JCO.2013.54.6911

B. Rini, B. Escudier, and P. Tomczak, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1939, 2011.
DOI : 10.1016/S0140-6736(11)61613-9

. Motzer, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

R. Motzer, A. Alyasova, D. Ye, A. Karpenko, H. Li et al., Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4), Annals of Oncology, vol.27, issue.3
DOI : 10.1093/annonc/mdv612

R. Motzer, C. Porta, and N. Vogelzang, Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial, The Lancet Oncology, vol.15, issue.3, pp.286-296, 2014.
DOI : 10.1016/S1470-2045(14)70030-0

D. Lorenzo, G. Buonerba, C. Federico, and P. , Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma, European Urology, vol.58, issue.6, pp.906-917, 2010.
DOI : 10.1016/j.eururo.2010.09.008

A. Pham, D. Ye, and S. Pal, Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma, Urologic Oncology: Seminars and Original Investigations, vol.33, issue.12, pp.517-527, 2015.
DOI : 10.1016/j.urolonc.2015.07.020

A. Amin, E. Plimack, J. Infante, M. Ernstoff, B. Rini et al., Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), 2014.